

## Intramolecular Pictet-Spengler reaction of N-alkoxy tryptamines I. Synthesis of (±)-Deamino-debromo-Eudistomin L.


Pedro H.H.Hermkens<sup>+</sup>, Jan H.v.Maarseveen<sup>+</sup>, Chris G.Kruse\*, Hans W.Scheeren<sup>+</sup>\*

<sup>+</sup> Department of Organic Chemistry, University of Nijmegen, Toernooiveld, 6525 ED Nijmegen, The Netherlands.

\* Duphar Research Laboratories, P.O.B. 2, 1380 AA Weesp, The Netherlands.

**Abstract:** The Eudistomin analogue **1f** was prepared in four steps with high overall yield (50%) from N-hydroxytryptamine **3a**. The key step in this reaction sequence is an intramolecular Pictet-Spengler cyclization reaction.

The increased research on secondary metabolites with interesting pharmacological activities has led to the discovery of the class of indole alkaloids containing a tetrahydro- $\beta$ -carboline fragment annulated with a oxathiazepine unit. These compounds -the Eudistomins (**1a-1e**)- were isolated from *Eudistoma olivaceum*<sup>1</sup> and more recently also from *Ritterella sigillinoides*<sup>2,4b</sup>. They display potent activity against *Herpes simplex* Type 1 (HSV-1) and *Polio* vaccine Type I viruses. Because of its unique structure and the antiviral activity, this class of compounds constitute a major challenge for total synthesis<sup>3</sup>. Common in the present approaches is the first step, to construct the C-ring by a




	R <sub>1</sub>	R <sub>2</sub>	R <sub>3</sub>
<b>Eudistomin L</b>			
<b>a:</b>	H	Br	H
<b>K</b>	H	H	Br
<b>C</b>	H	OH	Br
<b>E</b>	Br	OH	H
<b>e:</b>	H	H	H


Pictet-Spengler reaction of **3a** and a cysteinal derivative. However, subsequent ringclosure of the oxathiazepine ring appeared a difficult task and only recently two reports appeared of a total synthesis of eudistomin L<sup>4</sup>.

We have demonstrated<sup>5</sup> by the synthesis of corynanthe analogs with a tetrahydro 1,2-oxazines-D-ring that an intramolecular Pictet-Spengler ringclosure of N-alkoxytryptamine derivatives is an appropriate method for constructing the tetracyclic N-oxo- $\beta$ -carboline alkaloid framework with a high overall yield. In this approach ring C and D are formed simultaneously. We reasoned that this methodology for constructing tetracyclic indole alkaloids could also be suitable for an approach to the Eudistomin series. We now report the synthesis of (±)-Deamino-debromo-Eudistomin L (**1f**) via an intramolecular Pictet-Spengler reaction of **2a** or **2b** (see, retrosynthetic scheme below).

As the retrosynthetic scheme shows the intermediate for the intramolecular cyclization **2** could be build up by a coupling reaction of **3a** and the  $\alpha$ -chloromethylsulfides **4**. It has been demonstrated<sup>5</sup> that TEOC-protected N-hydroxytryptamine (**3b**) can be O-alkylated by alkylhalogenides in the presence of NaI, followed by deprotection to give N-alkoxytryptamines in good yields in a one-pot synthesis. Treatment of **3a** with 2-(trimethylsilyl)ethylchloroformate in dichloromethane/dioxan at room temperature gave **3b** (96% yield).



The  $\alpha$ -chloromethyl sulfide **4a** could be prepared in 3 steps starting from the thioacetate **5**<sup>7</sup>. A stirred solution of **5**, trimethyl orthoformate and a few drops of TFA (MeOH, 24h) gave the dimethylacetal **6** (81% yield). Dropwise addition of a methanolic 1N NaOMe solution (1 equiv.) to **6** in methanol gave the thiol **7** (70% yield). A phase-transfer alkylation reaction of **7** with bromochloromethane using powdered KOH (1.4 equiv.), catalyzed by triethylbenzylammoniumchloride (TEBAC) (0.1 equiv.) resulted in the quantitative formation of **4a**. The  $\alpha$ -chloromethyl sulfide **4b** was prepared in an




analogous fashion from methyl 3-mercaptopropionate (98% yield).

The freshly prepared anion of the N-hydroxyurethane derivative **3b** (DME/NaH(1.1 equiv.), 0°C) was added dropwise to the functionalized  $\alpha$ -chloromethylsulfides **4a** or **4b** in the presence of NaI in DME at roomtemperature. The alkylated products were not isolated, but deprotected immediately by adding Bu<sub>4</sub>NF (2 equiv.) to give the compounds **2a** and **2b** in an overall yield of 70% and 81%, respectively. An intramolecular Pictet-Spengler reaction occurred on treatment of **2a** in dichloromethane with trifluoroacetic acid (2 equiv.). After stirring for 3 days at roomtemperature, ( $\pm$ )-Deamino-debromo-Eudistomin L (**1f**) was isolated in a reasonable yield of 71%. The NMR data of **1f** shows a great resemblance with **1e**<sup>4b</sup> as far as characteristic shifts and coupling constants are

concerned.

After the reduction of the methylester of **2b** with DIBAL (2 equiv.) at  $-70^{\circ}\text{C}$  in toluene, TFA (3 equiv.) was added and intramolecular cyclization of intermediate **8** occurred at  $-70^{\circ}\text{C}$  within 15 minutes to give **1f** (61% yield). The difference in reactivity between the cyclization of **2a** and the intermediate **8** is enormous. Both cyclizations may proceed via **9**. In this case formation of **9** from **8** should be much faster than from **2a**. However, the difference in reactivity can also be explained by



supposing that the cyclization of **8** proceeds via an aldehyde intermediate.

In conclusion the successful synthesis of the model compound **1f**, demonstrates that the intramolecular Pictet-Spengler approach is suitable for constructing of the 7 membered oxathiazepine ring of the Eudistomin derivatives. Further work on the total synthesis of **1e** and **1a** is in progress and will be the subject of a full paper.

#### Acknowledgment

We thank Ad Swolfs for taking the 400 MHz COSY NMR spectrum of **1f**, through which proton assignment was possible. This work was supported by the Technology Foundation of the Netherlands (STW).

#### Spectroscopic data and Physical constants:

**Compound 6:** bp  $74\text{--}75^{\circ}\text{C}/4\text{mm}$ ;  $\eta^{25}$  1.4697; EIMS  $m/z$  178 ( $M^+$ );  $^1\text{H}$  NMR  $\delta$  4.45 (t, 1H,  $\text{HC}(\text{OMe})_2$ ), 3.34 (s, 6H,  $2\times\text{OCH}_3$ ), 2.92 (t, 2H,  $\text{CH}_2\text{S}$ ), 2.35 (s, 3H,  $\text{COCH}_3$ ), 1.84 (m, 2H,  $\text{CH}_2\text{CH}_2\text{S}$ ).

**Compound 7:** bp  $49^{\circ}\text{C}/4\text{mm}$ ;  $\eta^{25}$  1.4571; EIMS  $m/z$  136 ( $M^+$ );  $^1\text{H}$  NMR  $\delta$  4.43 (t, 1,  $\text{HC}(\text{OMe})_2$ ), 3.27 (s, 6H,  $2\times\text{OCH}_3$ ), 2.47 (m, 2H,  $\text{CH}_2\text{S}$ ), 1.92 (m, 2H,  $\text{CH}_2\text{CH}_2\text{S}$ ), 1.40 (t, 1H, SH)

**Compound 4a:** bp  $75\text{--}78^{\circ}\text{C}/3.5\text{ mm}$ ;  $\eta^{25}$  1.4970;  $^1\text{H}$  NMR  $\delta$  4.73 (s, 2H,  $\text{SCH}_2\text{Cl}$ ), 4.45 (t, 1H,  $\text{HC}(\text{OMe})_2$ ), 3.30 (s, 6H,  $2\times\text{OCH}_3$ ), 2.77 (t, 2H,  $\text{CH}_2\text{S}$ ), 1.91 (m, 2H,  $\text{CH}_2\text{CH}_2\text{S}$ ).

**Compound 4b:** CIMS  $m/z$  184 ( $[\text{M}+2]^+$ ), 182 ( $M^+$ ),  $^1\text{H}$  NMR  $\delta$  4.80 (s, 2H,  $\text{SCH}_2\text{Cl}$ ), 3.73 (s, 3H,  $\text{OCH}_3$ ), 3.18–2.58 (m, 4H,  $\text{CH}_2\text{CH}_2$ ).

**Compound 2a:** Oil; Rf 0.56 ( $\text{CHCl}_3/\text{MeOH}$ , 97/3, v/v); CIMS  $m/z$  325 ( $[\text{M}+1]^+$ ), 292 ( $[\text{M}-\text{MeOH}]^+$ ), 261 ( $[\text{C}_{14}\text{H}_{17}\text{N}_2\text{OS}]^+$ ), 189 ( $[\text{C}_{11}\text{H}_{13}\text{N}_2\text{O}]^+$ ), 130 ( $[\text{C}_9\text{H}_8\text{N}]^+$ );  $^1\text{H}$  NMR  $\delta$  8.03 (br s, 1H, indole NH), 7.67–7.08 (m, 5H, indole C(2)H and C(4)–C(7)H), 5.89 (br s, 1H, NH), 4.87 (s, 2H,  $\text{OCH}_2\text{S}$ ), 4.50 (t, 1H,  $\text{CH}(\text{OMe})_2$ ), 3.40 (s, 6H,  $2\times\text{OCH}_3$ ), 3.38 (m, 2H,  $\text{CH}_2\text{N}$ ), 3.05 (m, 2H, indole C(3) $\text{CH}_2$ ), 2.72 (t,

2H, CH<sub>2</sub>S), 1.99 (m, 2H, CH<sub>2</sub>CH(OMe)<sub>2</sub>).

**Compound 2b:** Oil; Rf 0.51 (CHCl<sub>3</sub>/MeOH, 97/3, v/v); EIMS 308 (M<sup>+</sup>), 188 ([C<sub>11</sub>H<sub>12</sub>N<sub>2</sub>O]<sup>+</sup>), 130 ([C<sub>9</sub>H<sub>8</sub>N]<sup>+</sup>), 86 ([C<sub>4</sub>H<sub>6</sub>O<sub>2</sub>]<sup>+</sup>); <sup>1</sup>H NMR δ 8.03 (br s, 1H, indole NH), 7.62-7.00 (m, 5H, indole C(2)H and C(4)-C(7)H), 5.89 (br s, 1H, NH), 4.83 (s, 2H, OCH<sub>2</sub>S), 3.64 (s, 3H, OCH<sub>3</sub>), 3.07 (br t, 2H, CH<sub>2</sub>N), 3.07-2.56 (m, 6H, indole C(3)CH<sub>2</sub> and SCH<sub>2</sub>CH<sub>2</sub>).

**Compound 1f:** mp 158-160°C (EtOAc/n-hexane); Rf 0.59 (n-hexane/EtOAc, 60/40, v/v); UV (MeOH) λ<sub>max</sub> 225, 274.5(sh), 281, 289.5 nm; CIMS (100 eV) m/z (relative intensity) 261 ([M+1]<sup>+</sup>, 53), 260 (M<sup>+</sup>, 100), 230 ([C<sub>13</sub>H<sub>14</sub>N<sub>2</sub>S]<sup>+</sup>, 34), 144 ([C<sub>10</sub>H<sub>10</sub>N]<sup>+</sup>, 72), 130 ([C<sub>9</sub>H<sub>8</sub>N]<sup>+</sup>, 86); <sup>1</sup>H NMR (400 MHz) δ 7.65 (br s, 1H, NH), 7.47 (d, 1H, <sup>3</sup>J=7.7 Hz, C(12)H), 7.31 (d, 1H, <sup>3</sup>J=7.7 Hz, C(9)H), 7.18-7.08 (m, 2H, C(10)-C(11)H), 5.08 and 5.01 (AB spectrum, 2H, <sup>2</sup>J=9.9 Hz, C(4)H<sub>2</sub>), 4.12 (br s, 1H, C(13b)H), 3.67 (m, 1H, C(7)H<sub>A</sub>), 3.11 (m, 1H, C(7)H<sub>B</sub>), 3.09 (m, 1H, C(2)H<sub>A</sub>), 3.05 (m, 1H, C(8)H<sub>A</sub>), 2.82 (m, 1H, C(2)H<sub>B</sub>), 2.78 (m, 1H, C(8)H<sub>B</sub>), 2.65 (m, 1H, C(1)H<sub>A</sub>), 2.10 (m, 1H, C(1)H<sub>B</sub>); <sup>13</sup>C NMR (400 MHz) δ 136.38 C(12a), 133.07 C(13a), 126.59 C(8b), 121.75 C(11), 119.65 C(10), 118.31 C(9), 110.78 C(12), 108.13 C(8a), 73.44 C(4), 63.05 C(C13b), 54.06 C(7), 37.96 C(2), 26.49 C(8), 20.17 C(1); Anal. Calc. for C<sub>14</sub>H<sub>16</sub>N<sub>2</sub>OS (Mw 260.360): C, 64.59; H, 6.19; N, 10.76. Found: C, 64.25; H, 6.17; N, 10.68.

## References

1. a) Rinehart, K.L., Jr.; Kobayashi, J.; Harbour, G.C.; Hughes, R.G.; Mizsak, S.A.; Scahill, T.A. *J. Am. Chem. Soc.* **1984**, *106*, 1524. b) Rinehart, K.L., Jr.; Kobayashi, J.; Harbour, G.C.; Gilmore, J.; Mascal, M.; Holt, T.G.; Shield, L.S.; Larfargue, F. *J. Am. Chem. Soc.* **1987**, *109*, 3378.
2. a) Blunt, J.W.; Lake, R.J.; Munro, M.H.G. *Tetrahedron Lett.* **1987**, *28*, 1825. b) Lake, R.J.; Brennan, M.M.; Blunt, J.W.; Munro, M.H.G.; Pannell, L.K. *Tetrahedron Lett.* **1988**, *29*, 2255.
3. a) Han, S.Y.; Lakshmikantham, M.V.; Cava, M.P. *Heterocycles* **1985**, *23*, 1671. b) Nakagawa, M.; Liu, J.J.; Ogata, K.; Hino, T. *Tetrahedron Lett.* **1986**, *27*, 6087. c) Plate R.; Hout v.R.H.M.; Behm, H.; Ottenheijm, H.C.J. *J. Org. Chem.* **1987**, *52*, 555. d) Nakagawa, M.; Liu, J.J.; Ogata, K.; Hino, T. *J. Chem. Soc. Chem. Commun.* **1988**, 463.
4. a) Still, I.W.J.; Strautmanis, J.R. *Tetrahedron Lett.* **1989**, *30*, 1041. b) Nakagawa, M.; Liu, J.J.; Hino, T. *J. Am. Chem. Soc.* **1989**, *111*, 2721.
5. Hermkens, P.H.H.; Maarseveen, v.J.H.; Kruse, C.G.; Scheeren, J.W. *J. Org. Chem.* in preparation.
6. a) Carpino, L.A.; Tsao, J.-H.; Ringsdorf, H.; Fell, E.; Hettrich, G., *J. Chem. Soc. Chem. Commun.*, **1978**, 358. b) Carpino, L.A.; Sau, A.C., *J. Chem. Soc. Chem. Commun.*, **1979**, 514.
7. Catch, J.R.; Cook, A.H.; Graham, A.R.; Heilbron, I. *J. Chem. Soc.* **1947**, 1609.

(Received in UK 24 July 1989)